

Half a Million Sharks Could Be Killed to Make Vaccine

By [Robert F. Kennedy Jr](#)

Global Research, October 03, 2020

[Children's Health Defense](#) 1 October 2020

Region: [USA](#)

Theme: [Science and Medicine](#)

Drug maker GlaxoSmithKline may need to slaughter [half a million sharks](#) to harvest [squalene](#), an oil made in shark livers, to make a new line of COVID jabs. Glaxo mixes squalene with a witches' brew of proprietary surfactants to produce its controversial AS03 vaccine adjuvant. Adjuvants are compounds that amplify immune response to hyperstimulate the immune system. They are associated with a variety of autoimmune diseases.

Scientific studies have linked squalene adjuvants to [Gulf War syndrome](#) and to a wave of debilitating [neurological disorders](#) including epidemics of narcolepsy caused by Glaxo's H1N1 Pandemrix vaccine during the 2009 swine flu "pandemic." One study showed a [13-fold increased risk](#) of narcolepsy in children who received Pandemrix.

The devastating cascade of brain injuries to children and health care workers forced the termination of that Glaxo vaccine after European governments used only a small fraction of the jabs they had purchased from Glaxo. A recent study [links squalene to carcinomas](#). In a bizarre and reckless twist, Glaxo has revived the dangerous adjuvant as its hall pass to the COVID-19 money orgy.

The company said it would manufacture a billion doses of this adjuvant for potential use in coronavirus vaccines. Around 3,000 sharks are needed to extract one ton of squalene.

[Shark Allies](#), a California-based group, said Glaxo will kill around 250,000 sharks to make enough AS03 for the world's population to receive one dose of its COVID-19 vaccine. If, as expected, [two doses are needed](#), half a million sharks must die.

Glaxo declared that it would be producing 1 billion doses of AS03 "to support the development of multiple adjuvanted COVID-19 vaccine candidates."

Glaxo has developed partnerships with multiple companies, including its behemoth rival Sanofi, China's Clover Biopharmaceuticals and Inovax Biotech in the city of Xiamen. Glaxo has also agreed to make the technology available to the Coalition for Epidemic Preparedness Innovations for COVID vaccines in Australia and elsewhere. Glaxo said it is focusing on what it considers a "proven technology" that will give the company "several shots on goal."

*

Note to readers: please click the share buttons above or below. Forward this article to your

email lists. Crosspost on your blog site, internet forums. etc.

The original source of this article is [Children's Health Defense](#)
Copyright © [Robert F. Kennedy Jr](#), [Children's Health Defense](#), 2020

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Robert F. Kennedy Jr](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca